Physician profile
Mark William Beyer
NPI 1396181137
$4,447.78
in general payments reported to CMS, 2019-2025
31 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $388 · 2021: $521 · 2022: $348 · 2023: $911 · 2024: $1,064 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.83 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $981.96 | 2019-2025 | Clareon, Rocklatan, Eysuvis |
| Bausch & Lomb Americas INC. | $620.03 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $486.89 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Sun Pharmaceutical Industries INC. | $429.97 | 2019-2025 | Cequa |
| Allergan, INC. | $317.44 | 2019-2021 | |
| Oyster Point Pharma, INC. | $282.57 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $177.23 | 2020-2024 | Vuity, Durysta, Alphagan P |
| Novartis Pharmaceuticals Corporation | $150.31 | 2019-2023 | |
| Biotissue Holdings INC. | $141.07 | 2021-2023 | |
| Dompe US, INC. | $139.14 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.98 | 2019-2020 | |
| Eyepoint US, INC. | $90.75 | 2019 | |
| Kala Pharmaceuticals, INC. | $69.45 | 2020-2022 | |
| Harrow Eye, LLC | $66.40 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $58.50 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $37.64 | 2019-2022 | |
| Glaukos Corporation | $36.69 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $27.80 | 2021 | |
| Merz Pharmaceuticals, LLC | $23.79 | 2021 | |
| Exact Sciences Corporation | $20.32 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $19.95 | 2025 | Spravato |
| Tarsus Pharmaceuticals, INC. | $19.88 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $18.52 | 2021 | |
| Lundbeck LLC | $18.50 | 2025 | Rexulti |
| Adlon Therapeutics L.P. | $15.78 | 2020 | |
| Sight Sciences, INC. | $15.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2022 | |
| Aerie Pharmaceuticals, INC. | $14.37 | 2019 | |
| Shire North American Group INC | $14.25 | 2019 | |
| Thea Pharma INC. | $13.16 | 2023 | Iyuzeh |
| Merck Sharp & Dohme LLC | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Beyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.